Cascadian Therapeutics was a Seattle-based biopharmaceutical company focused on developing targeted therapies for cancer. The company developed tucatinib (ONT-380), a highly selective HER2 inhibitor for HER2-positive breast cancer. Cascadian was acquired by Seattle Genetics in February 2018 for $614 million; tucatinib subsequently received FDA approval as Tukysa in 2020.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountJan 2018
Jan 2017
Jan 2010
Create a free account to see which investors have funded this company.
Create Free Account
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Food technology company creating plant-based meat and dairy products that replicate the taste and...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
